01—Abstract
Summary
Summary of the 10-K filed February 27, 2007. Cited figures are marked; the original filing is the authoritative source.
DexCom, Inc. filed its 2006 Form 10-K on February 27, 2007, reporting on its early commercialization efforts for its Short-Term Continuous Glucose Monitoring System (STS®).
The company received FDA approval for the STS in March 2006 and launched it shortly after. Despite commencing revenue generation, DexCom incurred a significant net loss of $46.6 milliona for the year, reflecting substantial investments in research and development, sales, marketing, and manufacturing infrastructure.
The company is actively working to establish market acceptance, build its sales force, and secure reimbursement from third-party payors, which are critical for future revenue growth. DexCom also faces ongoing challenges including manufacturing scale-up, potential product failures, patent litigation with Abbott Diabetes Care, and the competitive landscape within the diabetes monitoring market.
02—Key points
Key Highlights
- DexCom received FDA approval for its Short-Term Continuous Glucose Monitoring System (STS®) on March 24, 2006, and began commercial shipments shortly thereafter.
- The company generated $2.2 million in revenue in 2006, its first year of commercial sales, but reported a net loss of $46.6 million.
- Significant investments were made in research and development ($19.4 million) and selling, general, and administrative expenses ($21.1 million), including building a direct sales force.
- The company is actively pursuing reimbursement from third-party payors and has applied for a Healthcare Common Procedure Coding System (HCPCS) code.
- DexCom is developing next-generation products, including a seven-day STS sensor, and exploring in-hospital glucose monitoring.
- The company is involved in ongoing patent litigation with Abbott Diabetes Care, which could have a material adverse effect on its business.
- Manufacturing capacity expansion remains a challenge, with ongoing efforts to improve quality, yields, and throughput.
03—Questions
Frequently Asked Questions
What is DexCom's primary product as of the 2006 10-K filing?
DexCom's primary product is the Short-Term Continuous Glucose Monitoring System (STS®), which received FDA approval in March 2006 and was launched shortly thereafter. It is designed to help adults with diabetes detect glucose trends and patterns.
What was DexCom's financial performance in 2006?
In 2006, DexCom generated $2.2 million in revenue, marking its first year of commercial sales. However, the company incurred a significant net loss of $46.6 million, reflecting substantial investments in product development, sales, marketing, and manufacturing infrastructure as it scaled operations.
What are the key challenges DexCom faces?
DexCom faces several key challenges, including achieving market acceptance for its STS system, scaling manufacturing operations to meet demand, securing reimbursement from third-party payors, managing ongoing patent litigation with Abbott Diabetes Care, and competing against established medical device companies.
What is DexCom's strategy for future growth?
DexCom's strategy involves establishing its technology platform as a leader in continuous glucose monitoring, driving product adoption through its direct sales and marketing efforts, seeking broad reimbursement from payors, expanding product use to new patient populations and settings (like hospitals), and rapidly bringing new products to market.
04—Continue